Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.

Journal of thrombosis and haemostasis : JTH - 1 Mar 2021

Roopkumar Joanna, Poudel Shyam K, Gervaso Lorenzo, Reddy Chandana A, Velcheti Vamsidhar, Pennell Nathan A, McCrae Keith R, Khorana Alok A

Abstract excerpt

INTRODUCTION: Thromboembolism (TE) is common in patients with non-small cell lung cancer (NSCLC) and is associated with worse outcomes. Recent advances in the understanding of NSCLC have led to the identification of molecular subtypes such as anaplastic lymphocyte kinase (ALK) and epidermal growth factor receptor (EGFR) mutations. The association of these subtypes with risk of TE has not been fully explored....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Lymphocytes

Share to Receptor Protein-Tyrosine Kinases

Share to Venous Thromboembolism

Source

Identifiers

PMID: 33314597
DOI: 10.1111/jth.15215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.PMID 33314597Read ↗

Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer.Semantic proximity Read ↗

Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer.Semantic proximity Read ↗

Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.Semantic proximity Read ↗

Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study.Semantic proximity Read ↗

Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case-control study.Semantic proximity Read ↗

Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer.Semantic proximity Read ↗

Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study.Semantic proximity Read ↗

Incidence, risk factors, and outcome of advanced NSCLC patients receiving antiangiogenic therapy with thromboembolic events: a retrospective cohort studySemantic proximity Read ↗

Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis.Semantic proximity Read ↗

Lower lymphocyte percentage and higher platelet count as poor prognostic factors for patients with epidermal growth factor receptor–mutated lung adenocarcinoma receiving tyrosine kinase inhibitors as first-line treatmentSemantic proximity Read ↗

Management of nonbacterial thrombotic endocarditis (NBTE) in advanced non-small cell lung cancer (NSCLC) patients with driver mutation: two case reports.Semantic proximity Read ↗

Cumulative Incidence of Thromboembolism and Prognostic Impact of Stroke in BRAF V600E-mutant Non-small-cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.